Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model

Breast Cancer Research

Volumn 10, Issue 1, 2008, Pages

  Woditschka, Stephan ^a   Haag, Jill D ^a   Mau, Bob ^b   Lubet, Ronald A ^c   Gould, Michael N ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; TAMOXIFEN;

ANIMAL; ARTICLE; BREAST; BREAST TUMOR; DISEASE MODEL; DRUG EFFECT; FEMALE; RAT; WISTAR FURTH RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; BREAST; BREAST NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; PYRAZOLES; RATS; RATS, INBRED WF; SULFONAMIDES; TAMOXIFEN;

EID: 44849134522     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1864     Document Type: Article

References (28)

1. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001, 276:18563-18569. 10.1074/jbc.M010787200, 11278747.
2. Pereg D, Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 2005, 258:115-123. 10.1111/j.1365-2796.2005.01519.x, 16018788.
3. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002, 62:632-635.
4. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004, 31(2 Suppl 7):22-29. 10.1053/j.seminoncol.2004.03.042, 15179621.
5. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000, 60:2101-2103.
6. Jang TJ, Jung HG, Jung KH, O MK. Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int J Exp Pathol 2002, 83:173-182. 10.1046/j.1365-2613.2002.00228.x, 12485462.
7. Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC. Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett 2002, 184:7-12. 10.1016/S0304-3835(02)00201-X, 12104042.
8. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, Thaler HT, Muller WJ, Du B, Brown AM, Dannenberg AJ. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002, 62:5405-5407.
9. Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 2003, 12:1486-1491.
10. Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 2007, 96:575-582. 10.1038/sj.bjc.6603593, 17285134.
11. Brueggemeier RW, Díaz-Cruz ES, Li PK, Sugimoto Y, Lin YC, Shapiro CL. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol 2005, 95:129-136. 10.1016/j.jsbmb.2005.04.013, 15964185.
12. Díaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005, 90:2563-2570. 10.1210/jc.2004-2029, 15687328.
13. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 2006, 66:5504-5511. 10.1158/0008-5472.CAN-05-4076, 16707480.
14. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004, 291:2433-2440. 10.1001/jama.291.20.2433, 15161893.
15. Woditschka S, Haag JD, Waller JL, Monson DM, Hitt AA, Brose HL, Hu R, Zheng Y, Watson PA, Kim K, Lindstrom MJ, Mau B, Steele VE, Lubet RA, Gould MN. Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas. Cancer Res 2006, 66:6884-6891. 10.1158/0008-5472.CAN-05-1823, 16818667.
16. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388. 10.1093/jnci/90.18.1371, 9747868.
17. Wang B, Kennan WS, Yasukawa-Barnes J, Lindstrom MJ, Gould MN. Difference in the response of neu and ras oncogene-induced rat mammary carcinomas to early and late ovariectomy. Cancer Res 1992, 52:4102-4105.
18. Wang B, Kennan WS, Yasukawa-Barnes J, Lindstrom MJ, Gould MN. Carcinoma induction following direct in situ transfer of v-Ha-ras into rat mammary epithelial cells using replication-defective retrovirus vectors. Cancer Res 1991, 51:2642-2648.
19. Wang B, Kennan WS, Yasukawa-Barnes J, Lindstrom MJ, Gould MN. Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains. Cancer Res 1991, 51:5649-5654.
20. Thompson TA, Gould MN. Direct gene transfer into the mammary epithelium in situ using retroviral vectors. Methods in Mammary Gland Biology and Breast Cancer Research 2000, 245-257. New York: Kluwer Academic/Plenum, Ip MM, Asch BB.
21. Gerdes J, Lemke H, Baisch H, Wacker WW, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715.
22. Gerlach C, Golding M, Larue L, Alison M, Gerdes J. Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. Lab Invest 1997, 77:697-698.
23. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119:493-501. 10.1083/jcb.119.3.493, 1400587.
24. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols: Methods in Molecular Biology 2000, 365-386. Totowa, NJ: Humana Press, Krawetz S, Misener S.
25. Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 1991, 19:3998. 328497, 1861990, 10.1093/nar/19.14.3998.
26. Box GEP, Cox DR. An analysis of transformations. J Roy Stat Soc B Met 1964, 26:211-246.
27. Hollingsworth AB, Lerner MR, Lightfoot SA, Wilkerson KB, Hanas JS, McCay PB, Brackett DJ. Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen. Breast Cancer Res Treat 1998, 47:63-70. 10.1023/A:1005872132373, 9493977.
28. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Iezzi M, Ricci C, Astolfi A, Croci S, Marangoni F, Musiani P, Forni G, Lollini PL. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer 2003, 105:384-389. 10.1002/ijc.11092, 12704673.